ERBB2 and urothelial carcinoma: A multicenter phase II trial conducted by Hussain et al. showed that trastuzumab combined with chemotherapy significantly improved outcomes in advanced urothelial carcinoma patients with HER2-positive disease (DFS 9.3 month, OS 14.1 month) [140].